Mast cells drive Blueprint mega-deal
In one of the largest biopharmatic offers of 2025, Sanofi acquired BluePrint drugs for an initial payment of $ 9.1 billion. The agreement gives Paris -based pharmacy an approved drug for systemic mastocytosis as well as a large pipeline which will strengthen the presence of the company in immunological diseases. BluePrint drugs were launched in 2011 with the funding of the A series A of Third Rock Ventures and F-Prime Capital, and became public in 2015. It developed powerful tyrosine kinase inhibitors using new chemistry from its owner-composed library and artificial intelligence to improve its drug discovery processes.
BluePrint obtained its first approval in 2020 for the oral inhibitor of Tyrosine Kinase Ayvakit (Avapritinib), for the treatment of gastrointestinal stromal tumors. The Food and Drug Administration of the United States has granted more time extensions on labels in 2021 for advanced systemic mastocytosis and then indolent in 2023. Blueprint estimates that around 30,000 to 60,000 patients have systemic mastocytosis, a rare disorder that leads to the accumulation of mastocytes in various organs and tissues, in the United States.
